Johnson & Johnson has won a $1.67 billion patent infringement lawsuit against Abbott Laboratories over the pharmaceutical giants two competing rheumatoid arthritis drugs. A U.S. District Court jury in Marshall, Texas, ruled that Humira, the drug produced by Abbott, violated the patent of Johnson & Johnsons Remicade.
J&J wins $1.67 billion lawsuit against Abbott
We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed, said Kim Taylor, president of Centocor Ortho Biotech, a Horsham, Pa.-based J&J subsidiary, in a written statement.
Abbott Laboratories plans to appeal the ruling, a spokesman for the Abbott Park, Ill.-based company said. We are disappointed in this verdict, and we are confident in the merits of our case and that we will prevail on appeal, said Scott Stoffel, spokesman for Abbott.
Humira was approved by the Food and Drug Administration in December 2002. Remicade gained FDA approval in November 1999.
What do you think? Post a comment on this article and share your opinion with other readers. Submit your comments to Modern Healthcare Online at [email protected]. Please be sure to include your hometown and state, along with your organization and title.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.